Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.

@article{Meredith2013SixmonthIA,
  title={Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.},
  author={Ian T. Meredith and Stefan Verheye and Neil Weissman and Paul T Barragan and Douglas A. Scott and Mariano Vald{\'e}s Ch{\'a}varri and Nick E. J. West and Henning Kelb{\ae}k and Robert J. Whitbourn and Darren Walters and Jacek Kubica and Leif Thuesen and M{\'o}nica Masotti and Adrian P. Banning and Iwar Sj{\"o}gren and Rod Stables and Dominic J. Allocco and Keith D. Dawkins},
  journal={EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology},
  year={2013},
  volume={9 3},
  pages={308-15}
}
AIMS The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial. METHODS AND RESULTS EVOLVE recruited 291 patients from 29 centres. At six months, IVUS-assessed in-stent net volume obstruction was 3.40 ± 5.06… CONTINUE READING